Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7287361 | 1.00 | UGCG (0.62) | UGCG | |
| Hydrochloric Acid SCHEMBL9602283 | 1.00 | UGCG (0.62) | UGCG | |
| SCHEMBL2229552 | 0.99 | UGCG (0.63) | UGCG | |
| SCHEMBL2229557 | 0.99 | UGCG (0.63) | UGCG | |
| SCHEMBL9443266 | 0.99 | UGCG (0.63) | UGCG | |
| SCHEMBL3498038 | 0.90 | — | — | |
| SCHEMBL3498039 | 0.90 | — | — | |
| SCHEMBL2228215 | 0.83 | CHRNA7 (0.64) | — | |
| SCHEMBL2228214 | 0.83 | CHRNA7 (0.64) | — | |
| SCHEMBL7281094 | 0.83 | CHRNA7 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0190920-B1 | METHOD OF ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY WITH ARYLAMIDO (AND ARYLTHIOAMIDO)AZABICYCLOALKANES | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | disclosed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | disclosed |
| EP-0353372-B1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | disclosed |
| EP-0272052-B1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-07-08 | — | — | EP | disclosed |
| US-5025022-A | Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-06-18 | — | — | US | disclosed |
| US-5017580-A | Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-05-21 | — | — | US | disclosed |
| US-4908370-A | Antianxiety agents | A. H. ROBBINS COMPANY, INC. (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0353371-A1 | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| US-4863919-A | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0311724-A1 | Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1989-04-19 | — | — | EP | disclosed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | disclosed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | disclosed |
| US-4722834-A | Method of using 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide-N-oxides to control emesis caused by anticancer drugs | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0237281-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamide-N-oxides in the control of emesis caused by anticancer drugs | SYNTHELABO (FR) | 1987-09-16 | — | — | EP | disclosed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |